August 30, 2024 07:29 AM EDT

Novo offers detailed look at semaglutide’s cardiac outcomes in Phase 3 trial as it tees up resubmission

Ayisha Sharma

News Reporter

LONDON — After a recent spate of setbacks, Novo Nordisk has raised the curtain on data detailing semaglutide’s ability to cut the risk of heart failure …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo offers detailed look at semaglutide’s cardiac outcomes in Phase 3 trial as it tees up resubmission

Ayisha Sharma

News Reporter

Sign up to read this article for free.

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Exclusive: A male contraceptive may prevent 99% of pregnancies. Now it’s up to a small biotech to finish testing it

House passes Biosecure Act, sending Chinese biotech ban to Senate

GSK, iTeos rejuvenate struggling TIGIT space with positive Phase 2 Jemperli combo data in lung cancer

#ESMO24 roundup: New data on Amgen’s PRMT5 inhibitor seem lackluster, and Jazz’s HER2 antibody

Adcomm says Intercept's rare liver disease drug should not get full approval

No­vo of­fers de­tailed look at semaglu­tide’s car­diac out­comes in Phase 3 tri­al as it tees up re­sub­mis­sion

Ayisha Sharma

News Reporter

Sign up to read this article for free.

more like this

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Ex­clu­sive: A male con­tra­cep­tive may pre­vent 99% of preg­nan­cies. Now it’s up to a small biotech to fin­ish test­ing it

House pass­es Biose­cure Act, send­ing Chi­nese biotech ban to Sen­ate

GSK, iTeos re­ju­ve­nate strug­gling TIG­IT space with pos­i­tive Phase 2 Jem­per­li com­bo da­ta in lung can­cer

#ES­MO24 roundup: New da­ta on Am­gen’s PRMT5 in­hibitor seem lack­lus­ter, and Jazz’s HER2 an­ti­body

Ad­comm says In­ter­cep­t's rare liv­er dis­ease drug should not get full ap­proval

Novo offers detailed look at semaglutide’s cardiac outcomes in Phase 3 trial as it tees up resubmission

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Exclusive: A male contraceptive may prevent 99% of pregnancies. Now it’s up to a small biotech to finish testing it

House passes Biosecure Act, sending Chinese biotech ban to Senate

GSK, iTeos rejuvenate struggling TIGIT space with positive Phase 2 Jemperli combo data in lung cancer

#ESMO24 roundup: New data on Amgen’s PRMT5 inhibitor seem lackluster, and Jazz’s HER2 antibody

Adcomm says Intercept's rare liver disease drug should not get full approval